Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

We asked five academics with expertise in sexual health, nutrition, psychiatry, bioethics and drug policy. Here’s what they said.

Patients with PD-L1-positive metastatic triple-negative breast cancer reported improved emotional function and pain with sacituzumab govitecan plus pembrolizumab compared with chemotherapy plus ...

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...

In the latest trading session, Gilead Sciences (GILD) closed at $121.46, marking a -2.11% move from the previous day. This change lagged the S&P 500's 0.53% loss on the day. Elsewhere, the Dow lost 0.

GV- and Arch-backed Pelage Pharma is developing a first-of-its-kind topical stem-cell therapy that could redefine the $10B ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, ...